Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review

Ewelina Jakielska; Paweł Głuszak; Marta Walczak; Wiesław Bryl

doi:10.5114/pg.2023.126054

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review

Prz Gastroenterol. 2023;18(2):148-153. doi: 10.5114/pg.2023.126054. Epub 2023 Mar 23.

Authors

Ewelina Jakielska¹, Paweł Głuszak¹, Marta Walczak², Wiesław Bryl²

Affiliations

¹ Student Internal Medicine Research Society, Poznan University of Medical Sciences, Poznan, Poland.
² Department of Internal Medicine, Metabolic Disorders and Hypertension, Poznan University of Medical Sciences, Poznan, Poland.

Abstract

Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor. The increasing number of cases creates the need for new therapeutic methods aimed at improving patient outcomes. Recent studies have highlighted the relationship between MAFLD and proprotein convertase subtilisin/kexin type 9 (PCSK9). Based on the available data, PCSK9 inhibitors appear to have beneficial effects in patients with MAFLD, and they may be a treatment option in the future. Further research is necessary to better evaluate the efficiency of PCSK9 inhibitors in MAFLD treatment.

Keywords: PCSK9; fatty liver; non-alcoholic fatty liver disease.

Publication types

Review